$ALHC

Maroney Dawn Christine sold $70K of ALHC

Maroney Dawn Christine (President) sold 5,000 shares of Alignment Healthcare, Inc. (ALHC) at $14.00 on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maroney Dawn Christine
Published Aug 18, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
high confidence
Mentioned
$ALHC
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not include new operational, financial, or regulatory information.

02

Market read

Traders may note insider selling activity, but the 10b5-1 pre-arranged nature makes it a low-signal catalyst.

03

What to watch

The filing does not disclose reasons for the sale, and the share count ($70k) may be small relative to company size, limiting interpretability.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

This is an SEC Form 4 insider transaction for Alignment Healthcare, Inc., reported by its President.

Company-level read

Ticker impact

$ALHCNeutralHigh confidence
Context

Alignment Healthcare disclosed an insider open-market sale by President Maroney Dawn Christine of 5,000 shares at $14 on 2026-08-14.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted.

Evidence & confidence

The transaction is explicitly coded as an open-market sale and states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution about near-term execution or liquidity needs.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Maroney Dawn Christine

    President and reporting insider who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Why Alignment Healthcare (ALHC) Stock Is Up Today

Alignment Healthcare (ALHC) shares rose 8.6% after its subsidiary announced a new Medicare Advantage plan in Los Angeles and Orange counties. Analyst Ryan Langston lowered his price target to $12 but maintained a Buy rating, citing inpatient utilization pressure. The stock had fallen 13.4% the previous day due to a downgrade and regulatory concerns.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$ALHCHigh

ALHC Stock Slides As Legal, Cost, And Rating Pressures Mount

Alignment Healthcare Inc. (ALHC) stock fell 14.75% on October 9, 2026, amid concerns over Medicare Advantage reimbursement pressures, legal issues, and cost challenges. The company reported $1.34B in revenue and $36.6M in net income for the latest quarter, but negative cash flow raised concerns. CMS's 2027 Star Ratings and a whistleblower's accounting allegations further pressured the stock, with Barclays cutting its price target to $10.